AMGN240816P280000
- 0.32
- 0.000.00%
Amgen Newsroom
Amgen (AMGN.US) and Astrazeneca (AZN.US) received breakthrough therapy designation from the FDA for their first-in-class therapy for treating COPD.
Two companies are planning to launch phase III clinical trials in COPD patients.
Despite Lower Earnings Than Five Years Ago, Amgen (NASDAQ:AMGN) Investors Are up 83% Since Then
Why It Might Not Make Sense To Buy Amgen Inc. (NASDAQ:AMGN) For Its Upcoming Dividend
What Eli Lilly, Novo Nordisk Earnings Reveal About the Future of GLP-1 Sales
About 73% of the S&P 500 Names Beat on EPS During the Week - Earnings Scorecard
Notable Analyst Calls This Week: Disney, Super Micro and Amgen Among Top Picks
12 Out of 17 Healthcare Companies Beat Profit Estimates This Week- Earnings Scorecard
Redburn Atlantic Adjusts Amgen Price Target to $180 From $170, Maintains Sell Rating
Intel, Amgen Share Losses Contribute To Dow's 182-Point Drop
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Express News | Amgen's Hyderabad Site Can Accommodate up to 3,000 People and Will Be Operational in Q4 2024
Express News | Amgen to Open New Site in Hyderabad, India
Are Hedge Funds Bullish on Amgen Inc. (AMGN) Now?
The GLP-1 Makers to Add to Your Portfolio: Tema ETFs CEO
Dow Up 614 Points On Gains For Intel, Salesforce Shares
Amgen Options Trading: A Deep Dive Into Market Sentiment
RBC Capital raised Amgen's target price to $362.
RBC Capital has raised Amgen's target price from $332 to $362 and maintains an "outperform" rating.
Amgen Stock Slides on Lowered Guidance
Amgen Price Target Raised to $381.00/Share From $360.00 by TD Cowen
Amgen | 10-Q: Q2 2024 Earnings Report